Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis
| Autor: | Maria Luisa Scattoni, Gian Paolo Morgano, Franco De Crescenzo, Silvia Minozzi, Marina Davoli, Laura Amato, Holger J. Schünemann, Fabio Cruciani, Gian Loreto D'Alò, Zuzana Mitrova, Francesca Fulceri, Rosella Saulle, Franco Nardocci |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pediatrics
medicine.medical_specialty Adolescent Autism Spectrum Disorder Guidelines Placebo Irritability lcsh:Computer applications to medicine. Medical informatics Adolescents law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law medicine Humans Antipsychotics Child Children business.industry Research Public Health Environmental and Occupational Health General Medicine Anxiety Disorders Confidence interval 030227 psychiatry Meta-analysis Strictly standardized mean difference Attention Deficit Disorder with Hyperactivity Relative risk Quality of Life Systematic review Anxiety lcsh:R858-859.7 medicine.symptom business D2 blockers 030217 neurology & neurosurgery Antipsychotic Agents |
| Zdroj: | Health and Quality of Life Outcomes Health and Quality of Life Outcomes, Vol 19, Iss 1, Pp 1-19 (2021) |
| ISSN: | 1477-7525 |
| Popis: | Background The net health benefit of using antipsychotics in children and adolescents with ASD is unclear. This review was performed to provide the evidence necessary to inform the Italian national guidelines for the management of ASD. Methods We performed a systematic review of randomized controlled trials (RCTs) comparing antipsychotics versus placebo for the treatment of ASD in children and adolescents. For efficacy, acceptability and safety we considered outcomes evaluated by the guideline panel critical and important for decision-making. Continuous outcomes were analyzed by using standardized mean difference (SMD), and dichotomous outcomes by calculating the risk ratio (RR), with their 95% confidence interval (95% CI). Data were analyzed using a random effects model. We used the Cochrane tool to assess risk of bias of included studies. Certainty in the evidence of effects was assessed according to the GRADE approach. Results We included 21 RCTs with 1,309 participants, comparing antipsychotics to placebo. Antipsychotics were found effective on “restricted and repetitive interests and behaviors” (SMD − 0.21, 95% CI − 0.35 to − 0.07, moderate certainty), “hyperactivity, inattention, oppositional, disruptive behavior” (SMD − 0.67, 95% CI − 0.92 to − 0.42, moderate certainty), “social communication, social interaction” (SMD − 0.38, 95% CI − 0.59 to − 0.16, moderate certainty), “emotional dysregulation/irritability” (SMD − 0.71, 95% CI − 0.98 to − 0.43, low certainty), “global functioning, global improvement” (SMD − 0.64, 95% CI − 0.96 to − 0.33, low certainty), “obsessions, compulsions” (SMD − 0.30, 95% CI − 0.55 to − 0.06, moderate certainty). Antipsychotics were not effective on “self-harm” (SMD − 0.14, 95% CI − 0.58 to 0.30, very low certainty), “anxiety” (SMD − 0.38, 95% CI − 0.82 to 0.07, very low certainty). Antipsychotics were more acceptable in terms of dropout due to any cause (RR 0.61, 95% CI 0.48 to 0.78, moderate certainty), but were less safe in terms of patients experiencing adverse events (RR 1.19, 95% CI 1.07 to 1.32, moderate certainty), and serious adverse events (RR 1.07, 95% CI 0.48 to 2.43, low certainty). Conclusions Our systematic review and meta-analysis found antipsychotics for children and adolescents with ASD more efficacious than placebo in reducing stereotypies, hyperactivity, irritability and obsessions, compulsions, and in increasing social communication and global functioning. Antipsychotics were also found to be more acceptable, but less safe than placebo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink